Medtronic Stock News

Medtronic remains a "Buy" due to its undervalued stock, recent product launches, and resolved supply chain issues, despite underperformance over the past 7 months. The company posted solid Q2 results with revenue up 5.25% YoY and expects organic revenue growth of 4.75%-5% for fiscal 2025. Medtronic's strategic acquisitions and focus on innovation and efficiency are expected to drive sustainable...

You can pat yourself on the back if you're thinking of loading up your portfolio with dividend-paying stocks -- because they're surprisingly strong wealth builders. (If you weren't thinking of doing so, you can start now!

Robotic surgery used to be fodder for science fiction movies. Not anymore.

"Dividend Aristocrats

Investors looking for stocks to hold on to for a while might want to consider dividend-paying companies. Besides offering a regular stream of passive income, dividend stocks have generally outperformed their non-dividend peers over the long run.

GALWAY, Ireland , Dec. 5, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024.

Dividend Aristocrats are an attractive group of stocks for dividend growth investors because of their blue chip quality and proven track record. The stocks pay reliable dividends and grow their distributions annually, helping to compound returns and offset inflation.

Medtronic remains a buy due to its attractive valuation and steady EPS growth, despite recent sector-wide selling pressure and modest losses. Q2 results beat Wall Street expectations, with revenue up 5% year-over-year, and management raised FY 2025 revenue and earnings estimates. Key risks include supply chain issues, competition, policy changes, and currency fluctuations, but MDT's free cash f...